Ecuador: These 12 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Ecuador
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Ecuador: These 12 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026" DrugPatentWatch.com thinkBiotech, 2025 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Ecuador Patent SP066373
Patent Title: FORMA CRISTALINA BETA DE CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Ecuador Patent SP066375
Patent Title: FORMA CRISTALINA GAMMA DE CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can REZUROCK (belumosudil mesylate) generic drug versions launch?
Generic name: belumosudil mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 25, 2025
Generic Entry Controlled by: Ecuador Patent SP077836
Patent Title: COMPUESTOS MEJORADOS FARMACOCINÉTICAMENTE
REZUROCK is a drug marketed by Kadmon Pharms Llc. There are five patents protecting this drug.
This drug has forty-nine patent family members in twenty-seven countries.
See drug price trends for REZUROCK.
The generic ingredient in REZUROCK is belumosudil mesylate. One supplier is listed for this generic product. Additional details are available on the belumosudil mesylate profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Ecuador Patent SP078002
Patent Title: FORMULACIONES FARMACEUTICAS DE INHIBIDORES DE HDAC
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: Ecuador Patent SP077999
Patent Title: FORMULACIONES DE UNA SAL DE BUPROPION DE LIBERACIÓN MODIFICADA
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: Ecuador Patent SP109923
Patent Title: BROMHIDRATO DE BUPROPION Y APLICACIONES TERAPÉUTICAS
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can BOSULIF (bosutinib monohydrate) generic drug versions launch?
Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 01, 2025
Generic Entry Controlled by: Ecuador Patent SP078063
Patent Title: FORMAS CRISTALINAS DE 4-[(2,4-DICLORO-5-METOXIFENIL)AMINO]-6-METOXI-7-[3-(4-METIL-1-PIPERAZINIL)PROPOXI]-3-QUINOLINOCARBONITRILO Y MÉTODOS PARA SU PREPARACIÓN
BOSULIF is a drug marketed by Pf Prism Cv. There are five patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF
See drug price trends for BOSULIF.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: Ecuador Patent SP088150
Patent Title: INHIBIDORES MACROCICLICOS DEL VIRUS DE LA HEPATITIS C
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and thirty-nine patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2025
Generic Entry Controlled by: Ecuador Patent SP088394
Patent Title: FORMULACIÓN DE CÁPSULA DE PIRFENIDONA Y EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-three patent family members in forty-five countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-one suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can LYRICA CR (pregabalin) generic drug versions launch?
Generic name: pregabalin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2025
Generic Entry Controlled by: Ecuador Patent SP088422
Patent Title: COMPOSICIONES FARMACÉUTICAS SÓLIDAS QUE CONTIENEN PREGABALINA
This drug has thirty-seven patent family members in thirty-three countries.
See drug price trends for LYRICA CR.
The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this API. Fifty-six suppliers are listed for this generic product. Additional details are available on the pregabalin profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2025
Generic Entry Controlled by: Ecuador Patent SP14019136
Patent Title: COMBINACIONES FARMACÉUTICAS DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRA (NEP)
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are four patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in forty countries. There has been litigation on patents covering ENTRESTO SPRINKLE
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.
When can KOSELUGO (selumetinib sulfate) generic drug versions launch?
Generic name: selumetinib sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2025
Generic Entry Controlled by: Ecuador Patent SP088597
Patent Title: SAL DE SULFATO DE HIDRÓGENO NOVEDOSA
KOSELUGO is a drug marketed by Astrazeneca. There are five patents protecting this drug.
This drug has one hundred and ninety-eight patent family members in forty-four countries.
See drug price trends for KOSELUGO.
The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2026
Generic Entry Controlled by: Ecuador Patent SP088783
Patent Title: DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNIÓN A PLACAS AMILOIDES Y OBTENCIÓN DE IMÁGENES DE LAS MISMAS
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries.
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can LASTACAFT (alcaftadine) generic drug versions launch?
Generic name: alcaftadine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 31, 2026
Generic Entry Controlled by: Ecuador Patent SP088786
Patent Title: TRATAMIENTOS DE LAS ALERGIAS OCULARES
This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT
See drug price trends for LASTACAFT.
The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.